Won Ki Kang

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh et al. · The Lancet · 2017 · 2.2K citations · Full text

Esophageal Cancer, Gastrointestinal Oncology, Least Two +8

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

Răzvan Cristescu, Jeeyun Lee, Michael Nebozhyn et al. · Nature Medicine · 2015 · 2.2K citations

Gastrointestinal Oncology, Medicine, Molecular Analysis +10

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Seung Tae Kim, Răzvan Cristescu, Adam J. Bass et al. · Nature Medicine · 2018 · 1.7K citations

Gastrointestinal Oncology, Pd-1 Inhibition, Medicine +9

Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial

Jeeyun Lee, Do Hoon Lim, Sung Kim et al. · Journal of Clinical Oncology · 2011 · 801 citations

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

Yoon‐Koo Kang, Won Ki Kang, D.B. Shin et al. · Annals of Oncology · 2009 · 773 citations · Full text

First-line Therapy, Surgical Oncology, Gastrointestinal Oncology +7